2019-11-14T07:25:25-06:00 2018-12-31 410746749 CLIFTONLARSONALLEN LLP 610 W GERMANTOWN PIKE STE 400 PLYMOUTH MEETING PA 19462 990 2018-01-01 460902111 RTOG FOUNDATION INC RTOG 2157170834 1818 MARKET STREET NO 1720 PHILADELPHIA PA 191033653 WALTER J CURRAN JR CHAIRMAN 2157170834 2019-11-13 1 CONNIE M LIRA P00481097 2156433900 67.137.57.251 2019-11-13 10:44:14 ES P 40B1045984B6BD7CE0CB919AAE2F7A412AF27D98 F618A12DC35960BE0D59E059F65AE82E227DCE9A 2018 2020-03-31 21:24:44Z WALTER J CURRAN JR 1818 MARKET STREET NO 1720 PHILADELPHIA PA 191033653 9645069 0 X WWW.RTOG.ORG X 2012 PA TO ORGANIZE & PROVIDE FUNDING FOR CLINICAL COOPERTATIVE GROUP ACTIVITIES & RESEARCH IN ONCOLOGY. 7 7 0 8 0 0 8011850 7310029 0 2334727 3 11 4051 302 8015904 9645069 0 0 0 0 0 0 0 0 0 10074477 9286665 10074477 9286665 -2058573 358404 3676283 4229460 1592733 1787506 2083550 2441954 X THE MISSION OF RTOG FOUNDATION, INC. (RTOG) IS TO: (1) IMPROVE THE SURVIVAL OUTCOME AND QUALITY OF LIFE OF ADULTS WITH CANCER THROUGH THE CONDUCT OF HIGH-QUALITY CLINICAL TRIALS. (2) EVALUATE NEW FORMS OF RADIOTHERAPY DELIVERY AND TEST NEW SYSTEMIC AND TARGETED THERAPIES IN CONJUNCTION WITH RADIOTHERAPY IN THE CONTEXT OF CLINICAL RESEARCH. (3) PARTICIPATE AS ONE OF THREE MEMBER ORGANIZATIONS IN THE ACTIVITIES OF NRG ONCOLOGY FOUNDATION. (4) DEVELOP AND CONDUCT PRACTICE-CHANGING CLINICAL TRIALS FOR THE NCI NATIONAL CLINICAL TRIAL NETWORK (NCTN) THROUGH RTOG'S MEMBERSHIP IN NRG ONCOLOGY. (5) DEVELOP AND CONDUCT INDUSTRY-SUPPORTED CLINICAL TRIALS THAT ARE IMPORTANT TO RTOG'S RESEARCH MISSION. (6) PROVIDE FUNDING FOR BASIC, CLINICAL, AND TRANSLATIONAL INVESTIGATORS TO COLLABORATE WITH RTOG IN THE DEVELOPMENT OF BOTH BIOLOGIC AND BIOPHYSICAL TARGETED THERAPIES. (7) SUPPORT YOUNG INVESTIGATORS FROM MANY DISCIPLINES WITHIN THE RTOG RESEARCH ENTERPRISE THROUGH FELLOWSHIPS AND VARIOUS AWARDS. 0 0 8465690 0 2334727 1) IMPROVE THE SURVIVAL OUTCOME AND QUALITY OF LIFE OF ADULTS WITH CANCER THROUGH THE CONDUCT OF HIGH-QUALITY CLINICAL TRIALS 2) EVALUATE NEW FORMS OF RADIOTHERAPY DELIVERY AND TEST NEW SYSTEMIC AND TARGETED THERAPIES IN CONJUNCTION WITH RADIOTHERAPY IN THE CONTEXT OF CLINICAL RESEARCH 3) PARTICIPATE AS ONE OF THREE MEMBER ORGANIZATIONS IN THE ACTIVITIES OF NRG ONCOLOGY FOUNDATION 4) DEVELOP AND CONDUCT PRACTICE-CHANGING CLINICAL TRIALS FOR THE NCI NATIONAL CLINICAL TRIAL NETWORK (NCTN) THROUGH RTOG'S MEMBERSHIP IN NRG ONCOLOGY 5) DEVELOP AND CONDUCT INDUSTRY-SUPPORTED CLINICAL TRIALS THAT ARE IMPORTANT TO RTOG'S RESEARCH MISSION 6) PROVIDE FUNDING FOR BASIC, CLINICAL, AND TRANSLATIONAL INVESTIGATORS TO COLLABORATE WITH RTOG IN THE DEVELOPMENT OF BOTH BIOLOGIC AND BIOPHYSICAL TARGETED THERAPIES 7) SUPPORT YOUNG INVESTIGATORS FROM MANY DISCIPLINES WITHIN THE RTOG RESEARCH ENTERPRISE. 8465690 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 7 7 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 0 0 0 0 0 PA X THE ORGANIZATION 2157170834 1818 MARKET STREET NO 1720 PHILADELPHIA PA 191033653 X WALTER J CURRAN JR MD CHAIR 1.00 X X 0 0 0 MITCHELL MACHTAY MD PRESIDENT-SECRETARY-TREASURER 5.00 X X 0 0 0 HAK CHOY MD DIRECTOR 1.00 X 0 0 0 JAMES DIGNAM MD DIRECTOR 1.00 X 0 0 0 JEFF MICHALSKI MD DIRECTOR 1.00 X 0 0 0 SETH A ROSENTHAL MD DIRECTOR 1.00 X 0 0 0 MARIA WERNER-WASIK MD DIRECTOR 1.00 X 0 0 0 DEBORAH W BRUNER PHD DIRECTOR - LEFT OCT 2018 1.00 X 0 0 0 0 0 0 0 0 0 0 0 5444587 1865442 7310029 CONTRACT REVENUE 900099 2334727 2334727 2334727 11 11 REIMBURSEMENTS 621500 302 302 302 9645069 2334727 0 313 X 125472 125472 23180 23180 1001293 541560 459733 1225 1225 13197 12279 918 28194 28194 160524 91930 68594 43706 1547 42159 RESEARCH PROJECTS 7577349 7577349 PURCHASES 212831 212831 SITE EXPENSES 98700 98700 DUES & SUBSCRIPTIONS 994 994 9286665 8465690 820975 0 1644741 2251308 9956 9917 2021586 1968235 3676283 4229460 1592733 1787506 1592733 1787506 X 2083550 2441954 2083550 2441954 3676283 4229460 358404 0 X 0 0 0 X 41051 11936635 12286004 8011850 7310029 39585569 41051 11936635 12286004 8011850 7310029 39585569 5006996 34578573 3 11 14 10728 8163 4051 302 23244 39608827 2334727 0.87300 0.86020 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: REIMBURSEMENTS - 2015 AMOUNT: $ 10,728. 2016 AMOUNT: $ 8,163. 2017 AMOUNT: $ 4,051. 2018 AMOUNT: $ 302. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED FORM 990, PART VI, SECTION A, LINE 8B NO BOARD COMMITTEES HAVE BEEN FORMED AS OF THIS TIME. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY AN INDEPENDENT ACCOUNTING FIRM. THE RETURN WILL THEN BE REVIEWED BY THE SECRETARY-TREASURER AND APPROVED. THE RETURN WILL THEN BE MADE AVAILABLE FOR ALL DIRECTORS PRIOR TO ITS FILING. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY APPLIES TO DIRECTORS, PRINCIPAL OFFICER AND MEMBERS OF THE BOARD OF DIRECTORS (INTERESTED PERSON). IN CONNECTION WITH ANY ACTUAL OR POSSIBLE CONFLICT OF INTEREST, AN INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF THE FINANCIAL INTEREST AND BE GIVEN THE OPPORTUNITY TO DISCLOSE ALL MATERIAL FACTS TO THE DIRECTORS CONSIDERING THE PROPOSED TRANSACTION OR ARRANGEMENT. AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND ALL MATERIAL FACTS, AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE INTERESTED PERSON SHALL LEAVE WHILE THE DETERMINATION OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON BY THE REMAINING BOARD MEMBERS WHO SHALL DETERMINE IF A CONFLICT OF INTEREST EXISTS. IF THE REMAINING MEMBERS DETERMINE THAT AN ACTUAL CONFLICT EXISTS, THE INTERESTED PERSON WILL BE INFORMED OF THAT AND PROVIDED AN OPPORTUNITY TO EXPLAIN. THE REMAINING MEMBERS WILL TAKE DISCIPLINARY ACTION BASED ON THE INTERESTED PERSON'S RESPONSE AND/OR FURTHER INVESTIGATION WARRANTED BY THE CIRCUMSTANCES. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE MADE AVAIALABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G SUB-AWARD PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 529,640. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 529,640. STUDY TEAM SERVICES: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 439,231. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 439,231. CONTRACTED RT QA REVIEWS: PROGRAM SERVICE EXPENSES 11,920. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 11,920. OTHER PROFESSIONAL AND CONTRACTED SERVICES: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 20,502. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 20,502.